Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey

PLoS ONE

Volumn 13, Issue 2, 2018, Pages

  Kouyoumdjian, Fiona G ^a,b   Patel, Alexandra ^c   To, Matthew J ^b,d   Kiefer, Lori ^c,e   Regenstreif, Leonora ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e Ministry of Community Safety and Correctional Services   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE; NALOXONE; OPIATE AGONIST;

ADULT; CLINICAL PRACTICE; HEALTH CARE FACILITY; HEALTH CARE POLICY; HUMAN; MEDICAL STAFF; ONTARIO; PATIENT CARE; PATIENT SAFETY; PHYSICIAN; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PROVINCIAL CORRECTIONAL FACILITY; REVIEW; MALE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PRISON; QUESTIONNAIRE; UTILIZATION;

ADULT; BUPRENORPHINE; HUMANS; MALE; METHADONE; NALOXONE; ONTARIO; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRACTICE PATTERNS, PHYSICIANS'; PRISONS; SURVEYS AND QUESTIONNAIRES;

EID: 85042202299     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0192431     Document Type: Review

References (70)

1. Brink JH, Doherty D, Boer A. Mental disorder in federal offenders: A Canadian prevalence study. International journal of law and psychiatry. 2001; 24(4–5):339–56. PMID: 11521413
2. Nicholls TL, Lee Z, Corrado RR, Ogloff JRP. Women Inmates’ Mental Health Needs: Evidence of the Validity of the Jail Screening Assessment Tool (JSAT). The International Journal of Forensic Mental Health. 2004; 3(2):167–84.
3. A health care needs assessment of federal inmates in Canada. Canadian journal of public health = Revue canadienne de sante publique. 2004; 95 Suppl 1:S9–63. PMID: 15125459.
4. Crocker AG, Cote G, Toupin J, St-Onge B. Rate and characteristics of men with an intellectual disability in pre-trial detention. Journal of Intellectual & Developmental Disability. 2007; 32(2):143–52.
5. Rezansoff SN, Moniruzzaman A, Gress C, Somers JM. Psychiatric diagnoses and multiyear criminal recidivism in a Canadian provincial offender population. Psychology, Public Policy, and Law. 2013; 19 (4):443–53.
6. Power J, Usher, A. Correlates and trajectories to self-injurious behaviour in federally sentenced men. In: Correctional Service of Canada, editor. Ottawa: Research Report 250; 2011.
7. Elgar FJ, Knight J, Worrall GJ, Sherman G. Behavioural and substance use problems in rural and urban delinquent youths. Canadian Journal of Psychiatry—Revue Canadienne de Psychiatrie. 2003; 48 (9):633–6. https://doi.org/10.1177/070674370304800911 PMID: 14631885
8. Derkzen DM, Allenby K. Assessment of the Aboriginal Women’s Maintenance Program. Correctional Service of Canada, Ottawa, 2012.
9. Hopley AA, Brunelle C. Personality mediators of psychopathy and substance dependence in male offenders. Addictive Behaviors. 2012; 37(8):947–55. https://doi.org/10.1016/j.addbeh.2012.03.031PMID: 22543034
10. Mullins P, Farrell MacDonald S. Offender Substance Use Patterns–Aboriginal and Non-Aboriginal Offenders. Correctional Service of Canada, Ottawa, 2012.
11. Smith A, Cox K., Poon C., Stewart D., and McCreary Centre Society. Time Out III: A profile of BC youth in custody. Vancouver, BC: McCreary Centre Society, 2013.
12. Beaudette J. Prevalence of Mental Health Disorders Among Incoming Federal Offenders: Atlantic, Ontario, & Pacific Regions. Correctional Service of Canada, Ottawa: ERR-13-3; 2013.
13. Bland RC, Newman SC, Thompson AH, Dyck RJ. Psychiatric disorders in the population and in prisoners. International journal of law and psychiatry. 1998; 21(3):273–9. PMID: 9717090
14. Kouyoumdjian F, Calzavara LM, Kiefer L, Main C, Bondy SJ. Drug use prior to incarceration and associated socio-behavioural factors among males in a provincial correctional facility in Ontario, Canada. Canadian Journal of Public Health. 2014; 105(3):198–202.
15. Plourde C, Brochu S. Drugs in prison: a break in the pathway. Substance use & misuse. 2002; 37 (1):47–63.
16. Smith A, Cox K, Poon C, Stewart D, McCreary Centre Society. Time Out III: A profile of BC youth in custody. Vancouver, BC: McCreary Centre Society; 2013 [cited 2014 December 1]. Available from: http://www.mcs.bc.ca/pdf/Time_Out_III.pdf.
17. Plourde C, Brochu S, Gendron A, Brunelle N. Pathways of substance use among female and male inmates in Canadian federal settings. The Prison Journal. 2012; 92(4):506–24.
18. Zakaria D, Thompson JM, Jarvis A, Borgatta F. Summary of Emerging Findings from the 2007 National Inmate Infectious Diseases and Risk-Behaviours Survey Ottawa: Research Report R211; 2010 [cited 2014 June 16]. Available from: http://www.csc-scc.gc.ca/005/008/092/005008-0211-01-eng.pdf.
19. Kouyoumdjian FG, Calzavara L.M., Kiefer L., Main C., Bondy S.J. Drug use prior to incarceration and associated socio-behavioural factors among males in a provincial correctional facility in Ontario, Canada. Canadian Journal of Public Health. 2014; 105(3):198–202.
20. Murphy A, Chittenden M., and The McCreary Centre Society. Time Out II: A Profile of BC Youth in Custody. Vancouver, BC: The McCreary Centre Society, 2005.
21. Buxton JA, Rothon D, Durigon M, Lem M, Tu AW, Remple VP, et al. Hepatitis C and HIV prevalence using oral mucosal transudate, and reported drug use and sexual behaviours of youth in custody in British Columbia. Canadian Journal of Public Health- Revue Canadienne de Sante Publique. 2009; 100 (2):121–4. PMID: 19839288
22. Kunic D, Grant B.A. The Computerized Assessment of Substance Abuse (CASA): Results from the Demonstration Project. Correctional Service of Canada, Ottawa, 2006.
23. Martin RE, Gold F, Murphy W, Remple V, Berkowitz J, Money D. Drug use and risk of bloodborne infections: a survey of female prisoners in British Columbia. Canadian Journal of Public HealthRevue Canadienne de Sante Publique. 2005; 96(2):97–101.
24. Calzavara LM, Burchell AN, Schlossberg J, Myers T, Escobar M, Wallace E, et al. Prior opiate injection and incarceration history predict injection drug use among inmates. Addiction. 2003; 98(9):1257–65. PMID: 12930213
25. Grant B, Kunic D, MacPherson P, McKeown C, Hansen E. The High Intensity Substance Abuse Program (HISAP): Results from the Pilot Programs. Correctional Service of Canada, Ottawa, 2004.
26. Grant B, Varis DD, Lefebvre D. Intensive Support Units (ISU) for Federal Offenders with Substance Abuse Problems: An Impact Analysis. Correctional Service of Canada, Ottawa: Government of Canada; 2005.
27. Johnson S, MacDonald SF, Cheverie M. Characteristics of participants in the methadone maintenance treatment (MMT) program. Correctional Service of Canada, Ottawa, 2011.
28. Johnson S, Cheverie M, Moser A. Assessing the impact of enhanced drug interdiction activities at King-ton Penitentiary: A pilot study. Correctional Service of Canada, Ottawa, 2010.
29. Robinson D, Mirabelli, L. Summary of Findings of the 1995 CSC National Inmate Survey Ottawa, Can-ada1996 [cited 2014 November 18]. Available from: http://www.csc-scc.gc.ca/research/b14e-eng.shtml.
30. Canadian HIV/AIDS Legal Network. Canada: study provides further evidence of risk of hepatitis C and HIV transmission in prisons. HIV/AIDS Policy & Law Review / Canadian HIV/AIDS Legal Network. 2004; 9(3):45–6.
31. DeBeck K, Kerr T, Li K, Milloy MJ, Montaner J, Wood E. Incarceration and drug use patterns among a cohort of injection drug users. Addiction. 2009; 104(1):69–76. https://doi.org/10.1111/j.1360-0443.2008.02387.x PMID: 19133890
32. Burchell AN, Calzavara LM, Myers T, Schlossberg J, Millson M, Escobar M, et al. Voluntary HIV testing among inmates: sociodemographic, behavioral risk, and attitudinal correlates. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2003; 32(5):534–41. PMID: 12679706
33. Farrell S, Ross J, Ternes M, Kunic D. Prevalence of Injection Drug Use among Male Offenders. Correctional Service of Canada, Ottawa, 2010.
34. Martin RE, Hislop TG, Moravan V, Grams GD, Calam B. Three-year follow-up study of women who participated in a cervical cancer screening intervention while in prison. Canadian Journal of Public HealthRevue Canadienne de Sante Publique. 2008; 99(4):262–6. PMID: 18767267
35. Dufour A, Alary M, Poulin C, Allard F, Noel L, Trottier C, et al. Prevalence and risk behaviours for HIV infection among inmates of a provincial prison in Quebec City. AIDS. 1996; 10(9):1009–15. https://doi.org/10.1097/00002030-199610090-00012 PMID: 8853735
36. Ford PM, Pearson M, Sankar-Mistry P, Stevenson T, Bell D, Austin J. HIV, hepatitis C and risk behaviour in a Canadian medium-security federal penitentiary. Queen’s University HIV Prison Study Group. Qjm. 2000; 93(2):113–9. PMID: 10700482
37. Poulin C, Alary M, Lambert G, Godin G, Landry S, Gagnon H, et al. Prevalence of HIV and hepatitis C virus infections among inmates of Quebec provincial prisons. Canadian Medical Association journal. 2007; 177(3):252–6. https://doi.org/10.1503/cmaj.060760 PMID: 17664448
38. Zakaria D. Relationships between lifetime health risk-behaviours and self-reported human immunodeficiency virus and hepatitis C virus infection status among Canadian federal inmates: Research Report R-259; 2012 [cited 2014 June 16]. Available from: http://www.publicsafety.gc.ca/lbrr/archives/cn21491eng.pdf.
39. Thompson J, Zakaria D, Grant B. Aboriginal Men: A Summary of the Findings of the 2007 National Inmate Infectious Diseases and Risk-Behaviours Survey, R-237 Ottawa2011 [cited 2014 June 16]. Available from: http://www.csc-scc.gc.ca/research/005008-0237-eng.shtml.
40. Bell A, Trevethan S, Allegri N. A Needs Assessment of Federal Aboriginal Women Offenders. Correctional Service of Canada, Ottawa, 2004.
41. Groot E, Kouyoumdjian FG, Kiefer L, Madadi P, Gross J, Prevost B, et al. Drug Toxicity Deaths after Release from Incarceration in Ontario, 2006–2013: Review of Coroner’s Cases. PLoS One. 2016; 11 (7):e0157512. https://doi.org/10.1371/journal.pone.0157512 PMID: 27384044; PubMed Central PMCID: PMCPMC4934911.
42. Kouyoumdjian F, Kiefer L, Wobeser W, Hwang SW. High mortality over 12 years of follow up in people admitted to provincial custody in Ontario in 2000. CMAJ Open. 2016; 4(2):E153–61. https://doi.org/10.9778/cmajo.20150098 PMID: 27398358
43. Boutwell AE, Nijhawan A, Zaller N, Rich JD. Arrested on heroin: a national opportunity. J Opioid Manag. 2007; 3(6):328–32. PMID: 18290584.
44. Fullerton CA, Kim M, Thomas CP, Lyman DR, Montejano LB, Dougherty RH, et al. Medication-assisted treatment with methadone: assessing the evidence. Psychiatric services. 2014; 65(2):146–57. https://doi.org/10.1176/appi.ps.201300235 PMID: 24248468.
45. Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harvard review of psychiatry. 2015; 23(2):63–75. https://doi.org/10.1097/HRP.0000000000000075 PMID: 25747920.
46. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: the international experience. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2006; 43 Suppl 4:S197–215. https://doi.org/10.1086/508184 PMID: 17109307.
47. Mattick R, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003.
48. Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017; 357: j1550. https://doi.org/10.1136/bmj.j1550 PMID: 28446428; PubMed Central PMCID: PMCPMC5421454.
49. Perry AE, Neilson M, Martyn-St James M, Glanville JM, Woodhouse R, Godfrey C, et al. Pharmacological interventions for drug-using offenders. Cochrane Database Syst Rev. 2015; 6:CD010862. https://doi.org/10.1002/14651858.CD010862.pub2 PMID: 26035084.
50. Marsden J, Stillwell G, Jones H, Cooper A, Eastwood B, Farrell M, et al. Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. Addiction. 2017; 112(8):1408–18. https://doi.org/10.1111/add.13779 PMID: 28160345.
51. Degenhardt L, Larney S, Kimber J, Gisev N, Farrell M, Dobbins T, et al. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction. 2014; 109 (8):1306–17. https://doi.org/10.1111/add.12536 PMID: 24612249.
52. United Nations Office on Drugs and Crime. HIV/AIDS Prevention, Care, Treatment and Support in Prison Settings: A Framework for an Effective National Response. New York: United Nations; 2006.
53. United Nations Human Rights. Basic Principles for the Treatment of Prisoners. Office of the High Commissioner for Human Rights, 1990.
54. Methadone Treatment and Services Advisory Committee. Methadone Treatment and Services Advisory Committee: Final Report 2016. Available from: http://health.gov.on.ca/en/public/programs/drugs/ons/docs/methadone_advisory_committee_report.pdf.
55. Légaré F. Assessing barriers and facilitators to knowledge use [cited 2017 January 7]. Available from: http://ktclearinghouse.ca/knowledgebase/ktinhealthcare/3/4.
56. Kiefer L. Email communication on February 13, 2017. 2017.
57. Reitano J. Adult correctional statistics in Canada, 2015/2016. 2017. Available from: http://www.statcan.gc.ca/pub/85-002-x/2017001/article/14700-eng.htm.
58. Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug and alcohol dependence. 2009; 105(1–2):83–8. https://doi.org/10.1016/j.drugalcdep.2009.06.015 PMID: 19625142; PubMed Central PMCID: PMC2743749.
59. Walley AY, Alperen JK, Cheng DM, Botticelli M, Castro-Donlan C, Samet JH, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. Journal of general internal medicine. 2008; 23(9):1393–8. https://doi.org/10.1007/s11606-008-0686-x PMID: 18592319; PubMed Central PMCID: PMC2518016.
60. Gordon AJ, Kavanagh G, Krumm M, Ramgopal R, Paidisetty S, Aghevli M, et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychology of addictive behaviors: journal of the Society of Psychologists in Addictive Behaviors. 2011; 25(2):215–24. https://doi.org/10.1037/a0022776 PMID: 21480679.
61. Nosyk B, Anglin MD, Brissette S, Kerr T, Marsh DC, Schackman BR, et al. A call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health affairs. 2013; 32 (8):1462–9. https://doi.org/10.1377/hlthaff.2012.0846 PMID: 23918492; PubMed Central PMCID: PMC4570728.
62. Wakeman SE. Medications For Addiction Treatment: Changing Language to Improve Care. J Addict Med. 2017; 11(1):1–2. https://doi.org/10.1097/ADM.0000000000000275 PMID: 27898497.
63. Government of Canada. Methadone Program 2017 [updated April 27, 2017; cited 2017 August 11]. Available from: https://www.canada.ca/en/health-canada/services/health-concerns/controlledsubstances-precursor-chemicals/exemptions/methadone-program.html.
64. Cropsey KL, Binswanger IA, Clark CB, Taxman FS. The unmet medical needs of correctional populations in the United States. J Natl Med Assoc. 2012; 104(11–12):487–92. PMID: 23560350.
65. Springer SA, Bruce RD. A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners. J Opioid Manag. 2008; 4(2):81–6. PMID: 18557164; PubMed Central PMCID: PMCPMC2476214.
66. Kelsey CM, Medel N, Mullins C, Dallaire D, Forestell C. An Examination of Care Practices of Pregnant Women Incarcerated in Jail Facilities in the United States. Matern Child Health J. 2017; 21(6):1260–6. https://doi.org/10.1007/s10995-016-2224-5 PMID: 28236159.
67. College of Physicians and Surgeons of Ontario. Methadone Maintenance Treatment Program Standards and Clinical Guidelines, 4th Edition 2011 [cited 2017 January 13]. Available from: https://www.cpso.on.ca/uploadedFiles/members/MMT-Guidelines.pdf.
68. Kitson A, Straus SE. Section 3.2: Identifying the Knowledge-to-Action Gaps: Canadian Institutes of Health Research; 2011 [cited 2015 October 7]. Available from: http://www.cihr-irsc.gc.ca/e/43275.html.
69. Rudd RA, Seth P, David F, Scholl L. Increases in Drug and Opioid-Involved Overdose Deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016; 65(5051):1445–52. https://doi.org/10.15585/mmwr.mm655051e1 PMID: 28033313.
70. Young L. Fentanyl contributed to hundreds of deaths in Canada so far this year: Global News; 2017 [updated July 31, 2017; cited 2017 August 11]. Available from: http://globalnews.ca/news/3637148/fentanyl-overdoses-canada-2017/.